A Multi-Institutional Phase II Study of Single Agent Abraxane as Second Line Therapy in Patients With Advanced Transitional Cell Carcinoma of the Urothelium
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 14 Oct 2016 Status changed from recruiting to completed.
- 19 Jul 2011 Planned End Date changed from 1 Mar 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 28 Jan 2011 Celgene Corporation expect enrollment to be completed in 2011, according to a Celgene media release